Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.

Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.

1Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 2Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, ...

1Department of Oncology, University of Lausanne, Lausanne, Switzerland.

1Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York. 2Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.

Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts. *Corresponding Author: Serena C. Houghton, Department of Biostatistics and Epidemiology, ...

Cancer Res (2023) 83 (7_Supplement): ND02.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, ...

1University College London Cancer Institute, University College London, London, United Kingdom. *Corresponding Author: Bart Vanhaesebroeck, University College London, 72 Huntley Street, London WC1E ...

1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.

Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain. Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), ...

1Bioray Pharmaceutical Corp., San Diego, CA.